Jacobs Levy Equity Management Inc. Sells 115,494 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Jacobs Levy Equity Management Inc. reduced its holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) by 12.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 811,512 shares of the company's stock after selling 115,494 shares during the period. Jacobs Levy Equity Management Inc. owned 0.83% of Poseida Therapeutics worth $2,321,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new position in shares of Poseida Therapeutics in the 2nd quarter valued at about $31,000. Rothschild Investment LLC bought a new position in Poseida Therapeutics in the second quarter valued at approximately $35,000. Principal Financial Group Inc. acquired a new position in shares of Poseida Therapeutics during the 2nd quarter worth approximately $35,000. Intech Investment Management LLC bought a new stake in shares of Poseida Therapeutics during the 3rd quarter worth approximately $46,000. Finally, Mackenzie Financial Corp acquired a new stake in shares of Poseida Therapeutics in the 2nd quarter valued at approximately $51,000. 46.87% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Poseida Therapeutics

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the company's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total value of $278,100.00. Following the transaction, the chairman now directly owns 651,291 shares of the company's stock, valued at $6,037,467.57. This represents a 4.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 2.90% of the company's stock.

Poseida Therapeutics Stock Performance

Shares of PSTX traded up $0.03 during trading hours on Friday, hitting $9.36. The company had a trading volume of 805,186 shares, compared to its average volume of 2,491,911. The firm has a market cap of $912.23 million, a price-to-earnings ratio of -14.86 and a beta of 1.64. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The business has a fifty day moving average of $3.89 and a 200-day moving average of $3.32. Poseida Therapeutics, Inc. has a 12 month low of $1.87 and a 12 month high of $9.44.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on PSTX shares. William Blair restated a "market perform" rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Cantor Fitzgerald lowered shares of Poseida Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 26th. HC Wainwright reiterated a "neutral" rating and issued a $9.00 target price (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Piper Sandler downgraded Poseida Therapeutics from an "overweight" rating to a "neutral" rating and set a $10.00 price target on the stock. in a research report on Monday, December 2nd. Finally, BTIG Research restated a "neutral" rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Poseida Therapeutics presently has an average rating of "Hold" and a consensus target price of $9.50.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.